Please try another search
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Jeppe Ovli Ovlesen | 62 | 2024 | CEO & Director |
Anders Kronborg | 60 | 2024 | Chairman of Board |
Mauro Teixeira | - | - | Member of Scientific Advisory Board |
Sten Scheibye | 73 | 2024 | Director |
Vibeke S. Strand | - | 2024 | Member of Clinical Advisory Board |
Sten R. Sorensen | 65 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review